<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044524</url>
  </required_header>
  <id_info>
    <org_study_id>S334.1.004</org_study_id>
    <secondary_id>2009-017406-37</secondary_id>
    <secondary_id>01044524</secondary_id>
    <nct_id>NCT01044524</nct_id>
  </id_info>
  <brief_title>Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion</brief_title>
  <official_title>An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the absorption, distribution, metabolism and excretion after
      giving 2000 mg 14C-SLV334 via a 1-hour infusion. The absolute bioavailability will also be
      determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage excreted in urine and feces</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolic profile SLV334</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC, CL, lambda z, Cmax, t1/2, tmax and Vss</measure>
    <time_frame>16 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety variables</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLV 334</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SLV 334</intervention_name>
    <description>2000 mg via i.v. solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria healthy non-smoking subjects Exclusion Criteria QTc &gt; 430 ms; positive
        drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Vanderlaan</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Products</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S334.1.004 - Site 1</name>
      <address>
        <city>Zuid-Laren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <keyword>14C labeled ADME (Aborption Distribution Metabolism and Elimination) study</keyword>
  <keyword>Phase I</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

